Drugs /
mgc018
Overview
Clinical Trials
Mgc018 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating mgc018, 1 is phase 1/phase 2 (1 open).
ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for mgc018 clinical trials.
Breast carcinoma, head and neck squamous cell carcinoma, and melanoma are the most common diseases being investigated in mgc018 clinical trials [2].
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.